Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

• Status: Not yet recruiting
• Trial end date: 2022-12-01

Summary

This phase I trial studies the side effects and best dose of ivosidenib when given together with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Ivosidenib may stop the growth of cancer cells by blocking the IDH1 mutation and some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and filgrastim, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib with combination chemotherapy may work better in treating patients with acute myeloid leukemia compared to chemotherapy alone.

• Phase: Phase 1

Details

• Lead Sponsor: Northwestern University
• Collaborators: Agios Pharmaceuticals; National Cancer Institute (NCI)
• Treatments: Cytarabine; Fludarabine; Fludarabine phosphate; Glycine; Ivosidenib; Lenograstim; Sargramostim; Vidarabine